European Biotech Acquisition EBIT

As of the most recent data (December 2022), EBAC shows a EBIT of $-2.8M. That compares with $-1.1M in the prior-year period — down 156.2% year over year. That is above the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EBAC's EBIT is now $-2.8M (was $-1.1M) — a 156.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether European Biotech Acquisition is outperforming or lagging.

The its sector sector average EBIT is about $-63M. European Biotech Acquisition is at $-2.8M, which is higher that average. That is roughly 95.5% above the sector mean. Use the comparison chart on this page to see how EBAC stacks up against individual peers as well.

Tracking EBAC's ebit over time shows whether European Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.8M That compares with $-1.1M in the prior-year period — down 156.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has European Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-2.8M) with ownership activity and broader fundamentals.